Jim Simons
ALNY icon

Jim Simons’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jim Simons’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-64,400
Closed -$5.64M – 3357
2018
Q3 		$5.64M Sell
64,400
-311,000
-83% -$31.3M 0.01% 1726
2018
Q2 		$37M Buy
375,400
+140,000
+59% +$13.9M 0.04% 579
2018
Q1 		$28M Buy
235,400
+227,300
+2,806% +$29.3M 0.03% 746
2017
Q4 		$1.03M Buy
+8,100
New +$1.02M ﹤0.01% 2651
2017
Q2 		– Sell
-51,100
Closed -$2.62M – 3175
2017
Q1 		$2.62M Buy
+51,100
New +$2.36M ﹤0.01% 2094
2016
Q3 		– Sell
-18,673
Closed -$1.04M – 3305
2016
Q2 		$1.04M Sell
18,673
-195,327
-91% -$12.3M ﹤0.01% 2518
2016
Q1 		$13.4M Buy
+214,000
New +$14.2M 0.03% 929
2015
Q3 		– Sell
-102,399
Closed -$12.3M – 3143
2015
Q2 		$12.3M Buy
+102,399
New +$12.2M 0.03% 816
2014
Q2 		– Sell
-158,700
Closed -$10.7M – 2763
2014
Q1 		$10.7M Buy
+158,700
New +$12.3M 0.03% 827

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jim Simons's ALNY Position: Q4 2018 in Review

Jim Simons sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 64,400 shares — an estimated $5.64M sold.

Jim Simons first reported a position in ALNY in Q1 2014 and held it in 9 quarters. The position peaked at $37M in Q2 2018. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Jim Simons reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Jim Simons sold 64,400 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $5.64M.
  • Jim Simons first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 9 quarters.
  • Jim Simons's Alnylam Pharmaceuticals position peaked at $37M in Q2 2018.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Renaissance Technologies's 13F filing for Q4 2018, filed 13 Feb 2019.